Anson

ANTAEA Group of Companies is one of the largest Regional Clinical Research Organizations (CROs), providing high quality support in Southeast Europe, North Africa, Middle East and the Gulf Area.

The Group provides professional, yet flexible solutions, supporting our Clients to maximize their Research resources, in a cost effective manner. ANTAEA is dedicated to Services of scientific quality, management expertise, precision and reliable technology.

The Group includes integrated, marketing consultation services in our portfolio, based on Market Research, which cover products throughout their life cycle.

Specialities: Feasibility Projects, Initial Submissions, Amendments and Notifications to ECs (local and central) and Regulatory Authorities, Clinical Trials Monitoring in several different phases, Contracts for Clinical Trials Management, Contracts for Clinical Trial Rescue Projects, Design and Development of Clinical Trials Projects, Investigator Initiated Projects, Regulatory & Registration Projects (National, MRP, Variations etc.), Statistical Projects, Contracts for Investigator Training, Contract for Regulatory Services Training, Contract for Site Audit

ANTAEA also provides experienced CRAs to the Pharmaceutical and Biotechnology Industries and to CROs, in all the countries where ANTAEA is operating. ANTAEA training on procedures and setting standards and our technical support, guarantee uniformity in quality and timely delivery of projects.

Fountain Medical Development is a clinical contract research organization (CRO) offering a full range of ICH GCP compliant clinical research services in China, US, Japan, and Europe. FMD has extensive global experience in multiple therapeutic areas. The company has completed dozens of registrations trials which supported marketing authorization applications in US and Europe.

Our people is the basis of our success. The 1,700+ professionals are dedicated and diverse. At any given moment, at least 3 languages are spoken in our 20 offices in Asia, US, and Europe.

FMD is on the forefront of the paradigm shift in global clinical development. The regulatory reform in China has the potential to fundamentally change how an innovative therapy is developed. FMD is on the frontline building and shaping the future.

FMD is large enough to serve 7 out the 10 largest Pharma companies, and nimble enough to customize to the needs of startup firms.

In the US and Europe, FMD is doing business as FMD K&L. In China, we operate under the name FMD. Whatever the names are, the company is managed globally by a seasoned senior management team comprised of industry veterans.

Together we build a bright future.

FRACTALS is a Network of experts in social research and communication of actual & trends phenomena; it provides advice for strategies and innovations for products, ideas, services, no matter what field, dimension or investiment is involved.
Our approach incorporates several strategies from ethnography, marketing, trend forecasting, and is strongly 2.0 but with the awareness that no automatized platform can ever replace human analysis.

We are a CRO made by people full of passion and enthusiasm for their work. This is the main reason why our customers recommend us to others. The first 20 years of Hippocrates Research paved the way for our Company expertise and our people professional enrichment. Walking that path, we gained awareness of our possibilities and willingness to enthusiastically continue our work. Our wide-range experiences and competences allow us to offer diversified and innovative solutions in order to face our customers’ needs achieving the best results. We operate in 16 countries and 3 continents. Our range of services includes selection and identification of molecules, feasibility studies and project management for Phase I-to-IV Clinical Trials. In addition observational prospective and spontaneous and epidemiological studies. We assist our clients with concept-to-development projects and built-in marketing. Today, after more than 20 years work, we can say that our past was already rich of future!

OPIS is a European clinical CRO providing premium support for the management of global clinical trials from phase I to IV as well as pre- and post-marketing medical device investigations.
Founded in 1998, the company has 20 years of extensive experience in a wide range of therapeutic areas. Its recent oncology/immuno-oncology portfolio amounts to over 400 trials.
OPIS’s strength lies in its people and its specialized teams who assist clients from A-Z with medical writing, scientific and statistical consultancy for trial design and skilled teams of operational staff across Europe that ensure high quality project execution.
The OPIS e-clinical suite is developed to streamline digitalization of clinical data. Fully FDA 21 CRF Part 11 compliant and developed in close collaboration with the OPIS biometry and clinical operations units it offers:

• CLINICAL.NET, a modular and extremely user-friendly platform to handle all clinical trial data.
• A consolidated platform to handle named-patient programmes digitally.
• An investigator toolkit to facilitate and coordinate patient and clinician participation in clinical trials.

With flexible business models, OPIS clients come first and offers are truly shaped around individual Sponsor needs.

The OPIS teams are passionate about what they do and OPIS wants its name to stand for excellence.